The Year Of The Cure -- The Latest Breakthrough?

Here's a summary of another development in this, 'The Year Of The Cure'.

SO JAK INHIBITORS COULD YET STILL CURE ANDROGENIC ALOPECIA!?

HL2020 is generally conservative in outlining the prospects of new treatments. The tenor of this post, outlining JAK inhibitors for AGA, is unusually bullish. Following on from Kelopecia & Brotzu this is yet another reason to feel optimistic.  

http://www.hairlosscure2020.com/so-jak-inhibitors-could-yet-still-cure-androgenic-alopecia/

Aclaris Therapeutics was buying Vixen Pharmaceuticals (Dr. Angela Christiano and Columbia University affiliated company).  At first, when I read a one paragraph news alert summary of this acquisition, I did not think much of this development since I had been to Aclaris’ website in the past and remember reading that they only deal with Alopecia Areata related drugs.

However, I then read a lengthier article about this latest acquisition and some things (see below in red font) clearly stood out:

“As a result of this transaction, Aclaris acquired worldwide rights to intellectual property licensed to Vixen by Columbia University covering the use of certain Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata, androgenetic alopecia and other dermatological conditions.”

“The acquisition of the Vixen intellectual property and the licensed JAKPharm and Key Organics compounds solidifies Aclaris’ presence in the JAK inhibitor space and allows us to broaden our focus in hair loss to include androgenetic alopecia, often referred to as female or male pattern baldness,” said Neal Walker, President and Chief Executive Officer of Aclaris. [HT: Commentator Julian for pointing out that Mr. Walker is also CEO of Follica].

“We are delighted to enter into this agreement with Aclaris for the development of JAK inhibitors for alopecia areata, androgenetic alopecia, and other hair loss disorders,” said Dr. Christiano.”

So what makes you think they will put something out this year?

shaftless wrote:So what makes you think they will put something out this year?

JAK inhibitors are already FDA approved and various 'off-label' versions have been used by hair-loss sufferers. Let's see if this press-release and the anecdote are chased up by solid results.

If we're talking generally, this is a good article from Follicle Thought on other developments this year:

http://www.folliclethought.com/ultimate-guide-to-hair-regeneration-march-2015/